Prenetics Global (NASDAQ:PRE – Get Free Report) had its price target decreased by investment analysts at B. Riley Financial from $37.00 to $31.00 in a note issued to investors on Thursday, Benzinga reports. The firm presently has a “buy” rating on the stock. B. Riley Financial‘s price objective would suggest a potential upside of 252.27% from the company’s current price.
A number of other research firms also recently issued reports on PRE. Weiss Ratings restated a “sell (d-)” rating on shares of Prenetics Global in a research note on Thursday, October 15th. Lucid Cap Mkts upgraded shares of Prenetics Global to a “strong-buy” rating in a research note on Monday, October 12th. Maxim Group started coverage on shares of Prenetics Global in a report on Monday, October 26th. They issued a “buy” rating and a $41.00 price objective on the stock. Wall Street Zen raised shares of Prenetics Global from a “sell” rating to a “hold” rating in a report on Saturday, August 22nd. Finally, Craig Hallum began coverage on shares of Prenetics Global in a research report on Thursday, September 17th. They set a “buy” rating and a $40.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $36.17.
View Our Latest Stock Analysis on PRE
Prenetics Global Stock Performance
Prenetics Global (NASDAQ:PRE – Get Free Report) last posted its earnings results on Sunday, November 1st. The company reported ($1.45) earnings per share for the quarter. The firm had revenue of $64.11 million during the quarter. Prenetics Global had a negative net margin of 47.43% and a negative return on equity of 21.41%. As a group, sell-side analysts predict that Prenetics Global will post -2.36 EPS for the current fiscal year.
Insider Buying and Selling at Prenetics Global
In related news, CEO Danny Sheng Wu Yeung bought 17,181 shares of the firm’s stock in a transaction that occurred on Monday, August 24th. The shares were bought at an average cost of $21.23 per share, with a total value of $364,752.63. Following the acquisition, the chief executive officer owned 112,416 shares in the company, valued at $2,386,591.68. This trade represents a 18.04% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Brian Rosin bought 5,100 shares of the firm’s stock in a transaction that occurred on Tuesday, August 25th. The stock was bought at an average cost of $22.80 per share, for a total transaction of $116,280.00. Following the completion of the acquisition, the chief financial officer owned 23,100 shares in the company, valued at $526,680. This trade represents a 28.33% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 40,281 shares of company stock valued at $862,453 over the last 90 days. 7.80% of the stock is currently owned by company insiders.
Institutional Trading of Prenetics Global
A number of hedge funds and other institutional investors have recently bought and sold shares of PRE. Prospect Capital Advisors LLC purchased a new position in shares of Prenetics Global during the 3rd quarter valued at about $9,279,000. Pillsbury Lake Capital LLC purchased a new stake in Prenetics Global in the 3rd quarter worth approximately $4,407,000. Marshall Wace LLP purchased a new stake in Prenetics Global in the 3rd quarter worth approximately $3,643,000. Renaissance Technologies LLC increased its holdings in Prenetics Global by 85.1% in the 1st quarter. Renaissance Technologies LLC now owns 31,322 shares of the company’s stock worth $605,000 after acquiring an additional 14,400 shares in the last quarter. Finally, State Street Corp bought a new stake in Prenetics Global during the 3rd quarter worth approximately $264,000. Hedge funds and other institutional investors own 25.01% of the company’s stock.
Prenetics Global Company Profile
Prenetics Global Limited is a health sciences company focused on consumer wellness and health-related products. Its portfolio includes IM8, a consumer wellness brand offering nutritional supplements, and CircleDNA, a genetic testing service that provides reports on health, wellness and ancestry. The company has also operated clinical genomic testing services and provided COVID-19 testing during the pandemic. Its business has since shifted toward consumer health and wellness. Prenetics was founded in 2014 and is led by co-founder and Chief Executive Officer Danny Yeung.
Further Reading
- Five stocks we like better than Prenetics Global
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Prenetics Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prenetics Global and related companies with MarketBeat.com's FREE daily email newsletter.
